Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeltEx DRI and Temozolomide in Glioblastoma
NCT05664243Phase 2Active, not recruiting
- Sponsor
- IN8bio
- Start
- Sep 2023
- Primary completion
- Dec 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of INB-200 in glioblastoma (GBM) (3 arms), sponsored by IN8bio. Primary endpoints: Overall Survival at 12 months and Recommended Phase 2 Dose at 28 days. Started Sep 2023; status: active, not recruiting.
02
Drugs
INB-200
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05664243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05664243.